ES2903349T3 - Vector del VHS1 oncolítico y métodos de uso - Google Patents

Vector del VHS1 oncolítico y métodos de uso Download PDF

Info

Publication number
ES2903349T3
ES2903349T3 ES16789977T ES16789977T ES2903349T3 ES 2903349 T3 ES2903349 T3 ES 2903349T3 ES 16789977 T ES16789977 T ES 16789977T ES 16789977 T ES16789977 T ES 16789977T ES 2903349 T3 ES2903349 T3 ES 2903349T3
Authority
ES
Spain
Prior art keywords
tumor
cells
herpes simplex
viral vector
oncolytic herpes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16789977T
Other languages
English (en)
Spanish (es)
Inventor
Hiroshi Nakashima
Ennio Antonio Chiocca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Application granted granted Critical
Publication of ES2903349T3 publication Critical patent/ES2903349T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16671—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES16789977T 2015-05-04 2016-05-04 Vector del VHS1 oncolítico y métodos de uso Active ES2903349T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562156447P 2015-05-04 2015-05-04
PCT/US2016/030681 WO2016179226A1 (en) 2015-05-04 2016-05-04 Oncolytic hsv1 vector and methods of use

Publications (1)

Publication Number Publication Date
ES2903349T3 true ES2903349T3 (es) 2022-04-01

Family

ID=57218316

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16789977T Active ES2903349T3 (es) 2015-05-04 2016-05-04 Vector del VHS1 oncolítico y métodos de uso

Country Status (10)

Country Link
US (1) US10806761B2 (https=)
EP (2) EP3981438A1 (https=)
JP (1) JP6865736B2 (https=)
KR (1) KR102705177B1 (https=)
CN (1) CN108025088B (https=)
AU (2) AU2016257910B2 (https=)
CA (1) CA2988196C (https=)
DK (1) DK3291841T3 (https=)
ES (1) ES2903349T3 (https=)
WO (1) WO2016179226A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018169901A1 (en) * 2017-03-13 2018-09-20 Massachusetts Institute Of Technology Synthetic promoters
KR101974169B1 (ko) * 2018-08-10 2019-04-30 의료법인 성광의료재단 재조합 단순 헤르페스 바이러스 및 이의 제조방법
SG11202105422RA (en) * 2018-11-29 2021-06-29 Virogin Biotech Canada Ltd Hsv vector with reduced neurotoxicity
JP7671253B2 (ja) * 2019-03-14 2025-05-01 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 強力ながん治療薬としての合胞体腫瘍溶解性単純ヘルペス変異体
KR102333650B1 (ko) * 2019-11-08 2021-12-01 한국해양과학기술원 신규한 인간 상피세포성장인자 융합 단백질 및 이의 용도
US20240024392A1 (en) * 2020-12-04 2024-01-25 Immvira Co., Limited Oncolytic herpes simplex type 1 viruses for treatment of brain tumors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5728379A (en) 1994-06-23 1998-03-17 Georgetown University Tumor- or cell-specific herpes simplex virus replication
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
US6897057B1 (en) 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
US7214515B2 (en) 2001-01-05 2007-05-08 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic DNA inserts
WO2005080581A2 (en) 2004-02-17 2005-09-01 University Of Florida Research Foundation, Inc. Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression
AU2005235826A1 (en) 2004-03-31 2005-11-03 Tomoki Todo Method of constructing recombinant herpes simplex virus
DE602007010514D1 (de) * 2006-12-18 2010-12-23 Koninkl Philips Electronics Nv Bildkomprimierung und dekomprimierung
US8450106B2 (en) * 2007-10-17 2013-05-28 The Ohio State University Research Foundation Oncolytic virus
WO2009148488A2 (en) * 2008-05-29 2009-12-10 The General Hospital Corporation Use of oncolytic herpes viruses for killing cancer stem cells
ES2777183T3 (es) * 2012-11-14 2020-08-04 Brigham & Womens Hospital Inc Vectores oncolíticos de VHS1 y métodos de uso de los mismos

Also Published As

Publication number Publication date
EP3981438A1 (en) 2022-04-13
US10806761B2 (en) 2020-10-20
AU2016257910A1 (en) 2017-12-21
JP6865736B2 (ja) 2021-04-28
DK3291841T3 (da) 2022-01-10
WO2016179226A1 (en) 2016-11-10
CA2988196C (en) 2021-04-27
EP3291841B1 (en) 2021-10-20
CA2988196A1 (en) 2016-11-10
CN108025088B (zh) 2021-08-10
AU2021232778A1 (en) 2021-10-14
CN108025088A (zh) 2018-05-11
EP3291841A4 (en) 2018-12-05
KR20180037140A (ko) 2018-04-11
EP3291841A1 (en) 2018-03-14
KR102705177B1 (ko) 2024-09-11
JP2018518986A (ja) 2018-07-19
US20180133269A1 (en) 2018-05-17
AU2021232778B2 (en) 2024-12-19
AU2016257910B2 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
ES2903349T3 (es) Vector del VHS1 oncolítico y métodos de uso
ES2781852T3 (es) Vector de HSV oncolítico
US9862932B2 (en) Oncolytic virus therapy for resistant tumors
JP7184337B2 (ja) 細胞傷害性免疫細胞による攻撃に対してがん細胞を増感させるためのｎｋｇ２ｄ活性化リガンドタンパク質の発現
JPH10501990A (ja) 複製能力のある単純ヘルペスウイルスは新生細胞の破壊を媒介する
Li et al. Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: the key to breaking the log jam?
JPH11513390A (ja) 細胞殺傷のウイルス増強のための方法および組成物
JP5070583B2 (ja) ヒトグリオーマ治療に有用なリコンビナントｈｓｖ
Spencer et al. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy
ES2777183T3 (es) Vectores oncolíticos de VHS1 y métodos de uso de los mismos
G. Rainov et al. Clinical development of experimental virus-mediated gene therapy for malignant glioma
ES2276623B1 (es) Nuevos adenovirus recombinantes de replicacion condicionada (crad).
HK40063431A (en) Oncolytic hsv1 vector and methods of use
CN1871034B (zh) 用新型腺病毒治疗癌症的方法和组合物
Chen et al. Oncolytic virotherapy of cancer
HK1251177B (en) Oncolytic hsv1 vector and methods of use
Saha et al. Viral oncolysis of glioblastoma
WO2023081348A1 (en) Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells
Price et al. Herpes Simplex Virus 1 for Cancer Therapy
Zhang et al. 731. Completely Elimination of Xenograft SW620 Cancer by Combined Tumor Targeting MnSOD and Trail Genes
Mohr Herpes Simplex Virus as a Therapy for Cancer
Biotech LOW PATHOGENIC HUMAN ENTEROVIRUSES AS NOVEL ANTI-CANCER AGENTS AGAINST MALIGNANT GLIOMA
Cody et al. Preclinical Evaluation of a Genetically Engineered Herpes Simplex Virus Expressing Interleukin-12
Delivery 285. Transcriptional Targeting of HSV Vector-Mediated Transgene Expression to Specific Sensory Neuron Subtypes